Idelalisib is a small molecule inhibitor of PI3K-delta, an enzyme that is involved in B-cell receptor signaling, and has been approved for the treatment of chronic lymphocytic leukemia. The chemical name of Idelalisib is 5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone, the molecular formula is C22H18FN7O, and the formula weight is 415.42. The CAS No for Idelalisib is 3146702-54-6.
Top ten keywords and synonyms for Idelalisib include Idelalisib, ZYDELIG, CAL-101, GS-1101, PI3K inhibitor, chronic lymphocytic leukemia, CLL, relapsed/refractory follicular lymphoma, phosphoinositide 3-kinase, B-cell receptor signaling.
Health benefits of Idelalisib include the treatment of B-cell disorders such as chronic lymphocytic leukemia and follicular lymphoma. By inhibiting PI3K-delta, Idelalisib interferes with B-cell receptor signaling and can lead to the death of cancerous B-cells. In clinical trials, Idelalisib has been shown to be effective in treating relapsed or refractory chronic lymphocytic leukemia and follicular lymphoma.
Potential effects of Idelalisib include the death of cancerous B-cells and the inhibition of B-cell receptor signaling. By targeting PI3K-delta, Idelalisib can also interfere with other immune responses that require PI3K activity, such as T-cell and natural killer cell function.
The mechanism of action of Idelalisib is through the inhibition of PI3K-delta, which is a key enzyme in the signaling pathway of B-cells. PI3K-delta regulates the activation of Akt and other downstream signaling molecules which are important for the activation and proliferation of B-cells. By inhibiting PI3K-delta, Idelalisib interferes with B-cell receptor signaling and can lead to the death of cancerous B-cells.
Safety of Idelalisib has been evaluated in clinical trials, with the most common side effects including diarrhea, nausea, fatigue, cough, and fever. Other serious side effects that have been reported include infections, hepatotoxicity, pneumonitis, and colitis. Patients who are taking Idelalisib should be monitored closely for these potential side effects, and treatment should be discontinued if necessary.
Dosing information for Idelalisib depends on the patient's weight and the indication for treatment. The recommended dose for the treatment of chronic lymphocytic leukemia is 150mg twice a day, and the recommended dose for follicular lymphoma is 150mg twice a day in combination with rituximab. Patients should be instructed to take Idelalisib with food, and to avoid grapefruit and grapefruit juice while taking the medication.
In conclusion, Idelalisib is a small molecule inhibitor of PI3K-delta, and has been approved for the treatment of chronic lymphocytic leukemia and follicular lymphoma. Idelalisib targets B-cell receptor signaling and can lead to the death of cancerous B-cells. However, Idelalisib can interfere with other immune responses that require PI3K activity, such as T-cell and natural killer cell function. Patients who are taking Idelalisib should be monitored closely for potential side effects, and treatment should be discontinued if necessary. Dosing information for Idelalisib depends on the patient's weight and the indication for treatment. Overall, Idelalisib represents an important
